135 related articles for article (PubMed ID: 37987186)
1. Combining diabetes, sex, and menopause as meaningful clinical features associated with NASH and liver fibrosis in individuals with class II and III obesity: A retrospective cohort study.
Raverdy V; Chatelain E; Lasailly G; Caiazzo R; Vandel J; Verkindt H; Marciniak C; Legendre B; Bauvin P; Oukhouya-Daoud N; Baud G; Chetboun M; Vantyghem MC; Gnemmi V; Leteurtre E; Staels B; Lefebvre P; Mathurin P; Marot G; Pattou F
Obesity (Silver Spring); 2023 Dec; 31(12):3066-3076. PubMed ID: 37987186
[TBL] [Abstract][Full Text] [Related]
2. Prevalence and predictors of non-alcoholic steatohepatitis in subjects with morbid obesity and with or without type 2 diabetes.
Lembo E; Russo MF; Verrastro O; Anello D; Angelini G; Iaconelli A; Guidone C; Stefanizzi G; Ciccoritti L; Greco F; Sessa L; Riccardi L; Pompili M; Raffaelli M; Vecchio FM; Bornstein SR; Mingrone G; Gastaldelli A; Capristo E
Diabetes Metab; 2022 Sep; 48(5):101363. PubMed ID: 35760372
[TBL] [Abstract][Full Text] [Related]
3. Non-alcoholic fatty liver disease in pediatric type 2 diabetes: Metabolic and histologic characteristics in 38 subjects.
Newfield RS; Graves CL; Newbury RO; Schwimmer JB; Proudfoot JA; Say DS; Feldstein AE
Pediatr Diabetes; 2019 Feb; 20(1):41-47. PubMed ID: 30467936
[TBL] [Abstract][Full Text] [Related]
4. The roles of type 2 diabetes and obesity in disease activity and progression of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis.
Shinde S; Nelson DR; Mitroi J; Heaton PC; Hincapie AL; Brouwers B
Curr Med Res Opin; 2024 Jan; 40(1):59-68. PubMed ID: 37933187
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data.
Kabbany MN; Conjeevaram Selvakumar PK; Watt K; Lopez R; Akras Z; Zein N; Carey W; Alkhouri N
Am J Gastroenterol; 2017 Apr; 112(4):581-587. PubMed ID: 28195177
[TBL] [Abstract][Full Text] [Related]
6. Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD.
Bazick J; Donithan M; Neuschwander-Tetri BA; Kleiner D; Brunt EM; Wilson L; Doo E; Lavine J; Tonascia J; Loomba R
Diabetes Care; 2015 Jul; 38(7):1347-55. PubMed ID: 25887357
[TBL] [Abstract][Full Text] [Related]
7. Trimethylamine N-oxide levels are associated with NASH in obese subjects with type 2 diabetes.
León-Mimila P; Villamil-Ramírez H; Li XS; Shih DM; Hui ST; Ocampo-Medina E; López-Contreras B; Morán-Ramos S; Olivares-Arevalo M; Grandini-Rosales P; Macías-Kauffer L; González-González I; Hernández-Pando R; Gómez-Pérez F; Campos-Pérez F; Aguilar-Salinas C; Larrieta-Carrasco E; Villarreal-Molina T; Wang Z; Lusis AJ; Hazen SL; Huertas-Vazquez A; Canizales-Quinteros S
Diabetes Metab; 2021 Mar; 47(2):101183. PubMed ID: 32791310
[TBL] [Abstract][Full Text] [Related]
8. Growing burden of nonalcoholic fatty liver disease in Turkey: A single-center experience.
Yılmaz Y; Kanı HT; Demirtaş CÖ; Kaya E; Sapmaz AF; Qutranji L; Alkayyali T; Batun KD; Batman M; Toy B; Çiftaslan A
Turk J Gastroenterol; 2019 Oct; 30(10):892-898. PubMed ID: 31258138
[TBL] [Abstract][Full Text] [Related]
9. Clinical and sociodemographic determinants of disease progression in patients with nonalcoholic steatohepatitis in the United States.
Ruiz-Casas L; Pedra G; Shaikh A; Franks B; Dhillon H; Fernandes JDDR; Mangla KK; Augusto M; Schattenberg JM; Romero-Gómez M
Medicine (Baltimore); 2021 Dec; 100(50):e28165. PubMed ID: 34918671
[TBL] [Abstract][Full Text] [Related]
10. NAFLD improves risk prediction of type 2 diabetes: with effect modification by sex and menopausal status.
Kim Y; Chang Y; Ryu S; Wild SH; Byrne CD
Hepatology; 2022 Dec; 76(6):1755-1765. PubMed ID: 35514152
[TBL] [Abstract][Full Text] [Related]
11. Feasibility and efficiency of European guidelines for NAFLD assessment in patients with type 2 diabetes: A prospective study.
Besutti G; Bonilauri L; Manicardi E; Venturelli F; Bonelli E; Monelli F; Manicardi V; Valenti L; Ligabue G; Schianchi S; Massari M; Riva N; Froio E; Tagliavini E; Pattacini P; Giorgi Rossi P
Diabetes Res Clin Pract; 2021 Jul; 177():108882. PubMed ID: 34082056
[TBL] [Abstract][Full Text] [Related]
12. Poor glycaemic control and ectopic fat deposition mediates the increased risk of non-alcoholic steatohepatitis in high-risk populations with type 2 diabetes: Insights from Bayesian-network modelling.
Waddell T; Namburete A; Duckworth P; Fichera A; Telford A; Thomaides-Brears H; Cuthbertson DJ; Brady M
Front Endocrinol (Lausanne); 2023; 14():1063882. PubMed ID: 36909341
[TBL] [Abstract][Full Text] [Related]
13. Risk factors for fibrosis progression in non-alcoholic steatohepatitis: Analysis of the European cohort in the real-world GAIN study.
Shaikh A; Pedra G; Ruiz-Casas L; Franks B; Dhillon H; Fernandes JDDR; Mangla KK; Augusto M; Romero-Gómez M; Schattenberg JM
Gastroenterol Hepatol; 2024 May; 47(5):463-472. PubMed ID: 37890583
[TBL] [Abstract][Full Text] [Related]
14. [Prevalence and clinical features of non-alcoholic steatohepatitis in a hypertensive population].
García-Carretero R; Barquero-Pérez O; Mora-Jiménez I; Soguero-Ruiz C; Goya-Esteban R; Rodríguez-Castro C; Ramos-López J
Hipertens Riesgo Vasc; 2019; 36(3):130-136. PubMed ID: 30655210
[TBL] [Abstract][Full Text] [Related]
15. Risk of liver-related events by age and diabetes duration in patients with diabetes and nonalcoholic fatty liver disease.
Zhang X; Wong GL; Yip TC; Cheung JTK; Tse YK; Hui VW; Lin H; Lai JC; Chan HL; Kong AP; Wong VW
Hepatology; 2022 Nov; 76(5):1409-1422. PubMed ID: 35334125
[TBL] [Abstract][Full Text] [Related]
16. Protective effect of black relative to white race against non-alcoholic fatty liver disease in patients with severe obesity, independent of type 2 diabetes.
Browning MG; Khoraki J; DeAntonio JH; Mazzini G; Mangino MJ; Siddiqui MS; Wolfe LG; Campos GM
Int J Obes (Lond); 2018 Apr; 42(4):926-929. PubMed ID: 29437160
[TBL] [Abstract][Full Text] [Related]
17. Clinical features and treatment of nonalcoholic fatty liver disease across the Asia Pacific region-the GO ASIA initiative.
Chan WK; Treeprasertsuk S; Imajo K; Nakajima A; Seki Y; Kasama K; Kakizaki S; Fan JG; Song MJ; Yoon SK; Dan YY; Lesmana L; Ho KY; Goh KL; Wong VW
Aliment Pharmacol Ther; 2018 Mar; 47(6):816-825. PubMed ID: 29333610
[TBL] [Abstract][Full Text] [Related]
18. The triglycerides and glucose (TyG) index: A new marker associated with nonalcoholic steatohepatitis (NASH) in obese patients.
Rivière B; Jaussent A; Macioce V; Faure S; Builles N; Lefebvre P; Géraud P; Picot MC; Rebuffat S; Renard E; Paradis V; Servais MD; de Preville N; Nocca D; Lajoix AD; Pageaux GP; Galtier F;
Diabetes Metab; 2022 Jul; 48(4):101345. PubMed ID: 35339664
[TBL] [Abstract][Full Text] [Related]
19. Prospective direct comparison of non-invasive liver tests in outpatients with type 2 diabetes using intention-to-diagnose analysis.
Poynard T; Deckmyn O; Peta V; Paradis V; Gautier JF; Brzustowski A; Bedossa P; Castera L; Pol S; Valla D;
Aliment Pharmacol Ther; 2023 Nov; 58(9):888-902. PubMed ID: 37642160
[TBL] [Abstract][Full Text] [Related]
20. Association between weight change and risk of liver fibrosis in adults with type 2 diabetes.
Ke P; Xu M; Feng J; Tian Q; He Y; Lu K; Lu Z
J Glob Health; 2023 Oct; 13():04138. PubMed ID: 37856776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
